Navigation Links
Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
Date:9/22/2009

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- OrbusNeich today announced that the final 12-month clinical data from the global e-HEALING clinical study showed that the company's Genous Bio-engineered R stent is safe and effective in real world use, including in the treatment of patients with diabetes mellitus.

The study evaluated 4,987 of the 4,996 enrolled patients and found a target vessel failure (TVF) rate of 8.1 percent at 12 months with a follow-up rate of 92 percent, a target lesion revascularization (TLR) rate of 4.4 percent, a major adverse cardiac events (MACE) rate of 7.7 percent, a subacute thrombosis (SAT) rate of 0.5 percent and a late stent thrombosis (LST) of 0.3 percent. The combined SAT and late thrombosis rate of 0.8 percent was per protocol. Per Academic Research Consortium (ARC) definition, the definite and probable SAT and late thrombosis rate is 1.0 percent. The data were presented by Professor Robbert de Winter, M.D., Ph.D., of the Academic Medical Center in Amsterdam at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2009, in San Francisco.

"The excellent study design, electronic data capture and monitoring as well as comprehensive data management resulted in robust data for the e-HEALING clinical study, which further supports the efficacy and safety of the Genous Bio-engineered R stent," said de Winter, a co-principal investigator of the study. "We are especially pleased to see positive results in certain subsets of patients, such as diabetic patients, which often present as challenging cases with an expected higher incidence of in-stent-restenosis."

Twenty five percent of the patients in the study had diabetes mellitus. In a poster presentation, also at TCT 2009, de Winter and colleagues reported data from an analysis of this subset of the e-HEALING study. The 12-month follow-up from these 1,243 patients with diabetes mellitu
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cadient Group Selected as Finalist in Medical Marketing & Media Awards
2. Prix Galien USA Announces 2009 Final Candidates
3. Quest Diagnostics Announces Final Tender Offer Results
4. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
5. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
8. Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006
9. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
10. University of Maryland Announces Finalists for $75K Business Plan Competition
11. Impact Systems' Compliance-in-a-Box™ Video is Announced as "Be the Buzz of Bio" Contest Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 WABC Radio ... Your Pet with Lorry Young will be hosting California-based ... talk about stem cell therapy in pets. Dr. Harman ... benefits of stem cell therapy for pets suffering from osteoarthritis ... the Regenerative Veterinary Medicine industry forward. , Young has invited ...
(Date:7/25/2014)... The Conferee Networking committee is pleased ... Networking. These two-hour sessions provide a unique networking opportunity ... problems, discuss new techniques, or brainstorm new ideas in ... topic for consideration is August 31, 2014, and instructions ... Networking committee will review the topics, and status notifications ...
(Date:7/25/2014)... Lawrence Livermore scientists Charles Westbrook and William Pitz ... The World's Most Influential Scientific Minds ." , Westbrook ... were identified by analyzing citation data over the last ... work (2002-2012 and 2012-2013). The two were selected from ... , "This recognition is a great honor for Charlie ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... , , , , ... Primer anneal. temp. , Sensitivity , Specifi- , ... Tolerance , of non- , specific RNA , ... of serum components , Carry-over , prevention ...
... amplification of up to 3 kb genomic , DNA targets Cat. No. 1 647 679 ... 647 687 4 x 250 units (1 unit/l) , Cat. No. 1 146 165 100 ... Cat. No. 1 418 432 4 x 250 units (5 units/l) , ... 1 435 094 20 x 250 units (5 units/l) , , , , ...
... , Explore New Horizons in Amplification Yield, , ... High Yield, Accuracy, and the Prevention , of Carry-Over Contamination ... Roche Applied Science, which pioneered the blending , ... Long Template PCR Systems, now introduces the Expand High FidelityPLUS PCR , ...
Cached Biology Technology:Reverse transcriptases suitable for one-step RT-PCRb 2Taq DNA Polymerase 2Taq DNA Polymerase 3Expand High FidelityPLUS PCR System 2Expand High FidelityPLUS PCR System 3
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... provide much higher yield than their homozygous parents. Plant ... and used this effect called heterosis for richer harvests. ... underlying this phenomenon. Researchers at the University of Bonn ... decoded one possible mechanism in corn roots. More genes ...
... are known to be prodigious jumpers on land. Now, researchers ... , a Cell Press publication, have found that the tiny ... water, too. Their secret is a series of spring-loaded, oar-like ... have solved the most difficult task of jumping from the ...
... Grumman Corporation (NYSE: NOC ) has successfully ... biometric information system (ABIS) for the Australian Department of ... period to enable testing and refinement of analytical techniques ... the requirements for a future biometrics information management solution. ...
Cached Biology News:Corn: Many active genes - high yield 2Corn: Many active genes - high yield 3Pygmy mole crickets don't just walk on water, they jump on it 2Northrop Grumman Delivers Australian Automated Biometric Information System Trial Proof of Concept 2
Tube-O-DIALYZER Floats, small....
Feline Rhinotracheitis Virus...
Ezrin/Radixin/Moesin Antibody...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Biology Products: